<DOC>
	<DOCNO>NCT00175045</DOCNO>
	<brief_summary>The purpose study compare pharmacodynamics intravenous ( IV ) lansoprazole oral lansoprazole capsule , daily ( QD ) , participant erosive esophagitis .</brief_summary>
	<brief_title>Intravenous v Oral Lansoprazole Gastric Acid Secretion Subjects With Erosive Esophagitis</brief_title>
	<detailed_description>Phase 2 , open label , multi-center , 2-period study compare pharmacodynamics IV lansoprazole 30 mg oral lansoprazole 30 mg subject erosive esophagitis ( grade &gt; or= 2 ) diagnose endoscopy .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Subjects require Grade 2 , 3 4 esophageal finding accord TAP Grading Scale pretreatment endoscopy . Subjects must discontinue histamine H2receptor antagonists , proton pump ® inhibitor , prokinetic agent , antacid Carafate first dose drug study . Gastric duodenal ulcer ( lesion appreciable depth ≥3 mm ) hiatal hernia &gt; 5 cm . Subjects could diagnosis Barrett 's esophagus ( without dysplastic change ) . Coexisting systemic disease affect esophagus , ( ie , scleroderma , viral fungal infection ) , radiation therapy region esophagus , caustic physiochemical trauma esophagus . Current esophageal stricture require dilatation . The endoscope pas freely stomach endoscopy . Any stricture could dilate within 12 week begin Pretreatment Period . Positive H pylorus rapid urease test ( CLO® test KimberlyClark Corporation ) . Uncontrolled , clinically significant cardiovascular , pulmonary , renal , hepatic , metabolic , gastrointestinal , neurological endocrine disease abnormality ( erosive esophagitis disease study ) . Diagnosis ZollingerEllison syndrome , esophageal varix , symptomatic pancreaticobiliary tract disease , cholecystitis , rheumatoid arthritis , lupus , malignancy ( except basal cell carcinoma ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Intravenous</keyword>
	<keyword>gastric acid secretion</keyword>
	<keyword>Lansoprazole</keyword>
	<keyword>Esophagitis</keyword>
	<keyword>reflux</keyword>
</DOC>